XBIOTECH INC.

The board of XBiotech elected Jan‑Paul Simard effective October 23, 2026, as co‑chief executive officer alongside CEO Dr. Sushma Shivaswamy. Dr. Shivaswamy has been with the company for 17 years, previously served as CSO and has been interim CEO since December 2025; Simard has been at XBiotech since 2012 and brings experience in research, clinical development and study protocol development. The duo, with complementary skills, is intended to advance the development of the True‑Human antibody pipeline and drive operational execution. » More on finanzen.net

The FDA has cleared the IND for V‑SPINE (PT064) without a clinical hold, allowing XBiotech to begin the randomized, double‑blind, placebo‑controlled phase II study in the US. 150 participants are planned to receive 400 mg vilamakitug as 16 weekly subcutaneous injections or placebo; the primary endpoint is ASAS40 response at week 16. The study includes a 12‑week open‑label extension in which all participants receive vilamakitug and aims to assess the potential of IL‑1β blockade to treat inadequately controlled axSpA. » More on finanzen.net

XBiotech Inc. said that shareholders at the annual meeting approved all proposals recommended by the board of directors, including the election of five directors and the ratification of Whitley Penn LLP as auditors. Shareholders also approved the executives' performance-based compensation and the 2025 equity incentive plan. Dr. Thomas Kündig and Craig Rademaker were appointed to the board; Kündig will serve on the Compensation Committee and Rademaker on the Audit Committee. » More on de.investing.com